Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

CEPI will provide up to $25 million to the University of Oxford to complete early development of prototype vaccines against the Junín virus, while also looking to improve manufacturing speed and scale-up of ChAdOx technology. Learnings could be leveraged to inform vaccine design for related viruses from the Arenavirus family, giving the world a head start in rapidly responding to future outbreaks in as little as 100 days. First project to be initiated under CEPI and University of Oxford’s strategic partnership to accelerate global pandemic preparedness efforts.

Woman in a laboratory examining a sample

2 November 2023, Oslo, Norway and Oxford, UK – The Coalition for Epidemic Preparedness Innovations (CEPI) and the University of Oxford today announced the launch of a new project to initiate early development of prototype vaccines against the Junín virus, selected as an exemplar of the Arenavirus family which is responsible for multiple deadly haemorrhagic fevers with epidemic and pandemic potential. The data and materials generated by this project could give the world a head start in rapidly developing safe and effective vaccines against Arenaviruses within 100 days of their identification, potentially stopping a future pandemic in its tracks.

 CEPI will provide up to $25 million to Oxford for preclinical and Phase I clinical development of a vaccine against the Junín virus using Oxford’s ChAdOx platform – the basis for Oxford’s COVID-19 vaccine, which saved 6.3 million lives in the first year of the global vaccine rollout – and other rapid response platforms. Endemic to the Pampas of South America, a large region of over a million square kilometers which includes Buenos Aires, Junín virus can cause Argentine Haemmorhagic Fever, with symptoms including muscular pain, dizziness, rashes, and a 15-30% case fatality.


Read the full story on the University of Oxford website.

Similar stories

New small molecule found to suppress the evolution of antibiotic resistance in bacteria

Researchers from the Ineos Oxford Institute for antimicrobial research (IOI) and the Department of Pharmacology at Oxford University, have developed a new small molecule that can suppress the evolution of antibiotic resistance in bacteria and make resistant bacteria more susceptible to antibiotics.